ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
One-year outcomes of the PAUL glaucoma implant versus ahmed glaucoma valve for the treatment of glaucoma following cataract surgery.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated and compared the 1-year outcomes of the PAUL Glaucoma Implant (PGI) and the Ahmed Glaucoma Valve (AGV) in the management of aphakic glaucoma.
methodsA retrospective study was conducted on 30 eyes of 28 patients with aphakic glaucoma who underwent implantation of PGI (n = 10) or AGV (n = 20). Primary outcomes included surgical failure and success (complete or qualified). Secondary outcomes included intraocular pressure (IOP) reduction, best-corrected visual acuity (BCVA), medication use, and postoperative complications. Kaplan-Meier survival analysis was applied, with failure defined as IOP > 21 mmHg on two consecutive visits, implant removal, additional glaucoma surgery, or vision loss.
resultsAt 12 months, surgical success was achieved in 90% of PGI eyes and 75% of AGV eyes (p = 0.766). Complete success occurred in 30% (PGI) and 25% (AGV), while failure occurred in one PGI eye and five AGV eyes. Kaplan-Meier analysis revealed comparable cumulative success rates (p = 0.475). Mean IOP at 12 months was similar between groups (16.0 vs. 16.4 mmHg; p = 0.854), with significant reductions from baseline (PGI: p = 0.002; AGV: p < 0.001). Both groups showed reduced medication burden (p < 0.001), with PGI requiring fewer agents at 1-2 months (p = 0.024). BCVA remained stable. One complication was recorded, a case of choroidal haemorrhage in the AGV group; the hypotony episode was not classified as a complication as it resolved without visual loss or further surgical intervention.).
conclusionsPGI and AGV both effectively managed aphakic glaucoma. PGI demonstrated a trend toward higher success rates and fewer complications; however, these differences were not statistically significant. These findings suggest that PGI may be a favourable alternative, although larger prospective studies are needed to confirm this potential advantage.
Indexed as
Identifiers
42446677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.